However, we found that most acute myeloid leukemia (AML) cells, especially M4 and M5 subtypes, produce TNF and show basal level activation of RIP1/RIP3/MLKL signaling, yet do not undergo necroptosis.

But Mattias Carlsten, a hematologist at the Karolinska Institute, switched to studying natural killer (NK) cells when he realized that they offered a unique opportunity to treat blood cancers like ...

Dana-Farber Cancer Institute researchers have identified factors that determine whether donor lymphocyte infusion (DLI), a standard therapy for patients with acute myeloid leukemia (AML) who have ...

Leukemic stem cells (LSCs) and stemness signatures contribute to minimal residual disease in patients with acute myeloid ...

FLT3 -- A Therapeutic Target for AML? Because of its possible role in ... Relapses may also be due to the presence of several heterogeneous cell clones in the patients, some of which may not ...

AML = Acute myeloid leukemia; CK = Complex karyotype; ECOG = Eastern Cooperative Oncology Group; EORTC = European Organization for Research and Treatment of Cancer; GIMEMA = Italian Group for ...